

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION N	10. F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/088,538	10/088,538 06/10/2002		Thomas N. Masters	38151/203996	38151/203996 6926		
826	7590	06/25/2004	•	EXAM	EXAMINER		
	N & BIRD		TRAVERS, RUSSELL S				
101 SOUTH TRYON STREET, SUITE 4000			00	ART UNIT	PAPER NUMBER		
CHARLO	OTTE, NC	28280-4000		1617			

DATE MAILED: 06/25/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Advisory Action	10/088,538	MASTERS, THOMAS	N.
haveory heading	Examiner	Art Unit	
	Russell Travers, J.D.,Ph.D	1617	1
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence addre	ss
THE REPLY FILED 23 February 2004 FAILS TO PLACE Therefore, further action by the applicant is required to av final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this application and indication of the contraction of the contract of the c	ation. A proper reply to be places the application	to a on in
PERIOD FOR RE	PLY [check either a) or b)]		
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period o fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the content	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CF of extension and the corresponding amount the shortened statutory period for reply the later than three months after the mail	g date of the final rejection.  HE FINAL REJECTION. So  R 1.136(a) and the appropount of the fee. The approportionally set in the final Of	ee MPEP riate extension priate extension ffice action: or
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFR			
2. The proposed amendment(s) will not be entered be	ecause:		
(a) $oxed{\boxtimes}$ they raise new issues that would require furthe	er consideration and/or search (s	see NOTE below);	
(b)  they raise the issue of new matter (see Note be	elow);		
(c)  they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or simp	olifying the
(d)  they present additional claims without canceling	ng a corresponding number of fi	nally rejected claims.	
NOTE: See Continuation Sheet.			
3. Applicant's reply has overcome the following rejection	ion(s):		
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	parate, timely filed an	mendment
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☑ request for application in condition for allowance because: no n	reconsideration has been consideration has been consideration has been considerated arguments have been been been been been been been be	dered but does NOT pen presented.	place the
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were n	newly
7. For purposes of Appeal, the proposed amendment( explanation of how the new or amended claims wo	(s) a)⊠ will not be entered or b) ould be rejected is provided belo	☐ will be entered and w or appended.	d an
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed: <u>none</u> .  Claim(s) objected to: <u>none</u> .  Claim(s) rejected: <u>1-10</u> .  Claim(s) withdrawn from consideration:			
8. The drawing correction filed on is a) appro	oved or b) disapproved by the	ne Examiner.	
9. Note the attached Information Disclosure Statemen	·		
10. Other:	, , , , , , , , , , , , , , , , , , , ,		
		Russell Fravers, J.D., Primary Examiner Art Unit: 1617	,Ph.D

U.S. Patent and Trademark Office PTOL-303 (Rev. 11-03) Continuation of 2. NOTE: Examiner notes theraputic effect at 1/3 the claimed dosage obviates a higher dosage. Recitation of extended dosage levels would require additional search and consideration .